Really like this company a lot I suggest doing some dd. Had a big discount from the change in accounting for spacs and also part of ARK's portfolio. Besides those nuances I think this company has huge potential in the next few years in the genomics space.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.